Antazoline therapy of recurrent refractory supraventricular arrhythmias--a preliminary report.
Seven patients with chronic or recurrent supraventricular tachyarrhythmias were selected for a trial of antazoline therapy because sinus rhythm or a controlled ventricular response could not be achieved with quinidine, procainamide, digitalis or propranolol. Sinus rhythm was established by either intravenous administration of antazoline or direct-current countershock, and has been maintained in all for 4 to 16 months by oral administration of antazoline. Side effects were minor. Antazoline is a sufficiently promising antiarrhythmic agent to warrant large-scale controlled studies.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000865:Antazoline / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004077:Digoxin / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011342:Procainamide / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use; D012008:Recurrence
D007093:Imidazoles; D004077:Digoxin; D011433:Propranolol; D000865:Antazoline; D011802:Quinidine; D011342:Procainamide